|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: FXR2 |
Gene summary for FXR2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | FXR2 | Gene ID | 9513 |
| Gene name | FMR1 autosomal homolog 2 | |
| Gene Alias | FMR1L2 | |
| Cytomap | 17p13.1 | |
| Gene Type | protein-coding | GO ID | GO:0000375 | UniProtAcc | P51116 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 9513 | FXR2 | LZE7T | Human | Esophagus | ESCC | 6.22e-06 | 1.83e-01 | 0.0667 |
| 9513 | FXR2 | LZE24T | Human | Esophagus | ESCC | 1.49e-05 | 6.27e-02 | 0.0596 |
| 9513 | FXR2 | P1T-E | Human | Esophagus | ESCC | 6.06e-04 | 1.76e-01 | 0.0875 |
| 9513 | FXR2 | P2T-E | Human | Esophagus | ESCC | 4.56e-02 | 6.52e-02 | 0.1177 |
| 9513 | FXR2 | P4T-E | Human | Esophagus | ESCC | 7.48e-15 | 1.15e-01 | 0.1323 |
| 9513 | FXR2 | P5T-E | Human | Esophagus | ESCC | 6.95e-03 | -6.23e-02 | 0.1327 |
| 9513 | FXR2 | P8T-E | Human | Esophagus | ESCC | 8.04e-03 | 5.19e-02 | 0.0889 |
| 9513 | FXR2 | P9T-E | Human | Esophagus | ESCC | 2.40e-05 | 5.46e-02 | 0.1131 |
| 9513 | FXR2 | P10T-E | Human | Esophagus | ESCC | 3.81e-10 | 3.59e-02 | 0.116 |
| 9513 | FXR2 | P12T-E | Human | Esophagus | ESCC | 1.22e-08 | 9.30e-02 | 0.1122 |
| 9513 | FXR2 | P15T-E | Human | Esophagus | ESCC | 1.90e-08 | 5.66e-02 | 0.1149 |
| 9513 | FXR2 | P16T-E | Human | Esophagus | ESCC | 6.09e-10 | 3.31e-02 | 0.1153 |
| 9513 | FXR2 | P17T-E | Human | Esophagus | ESCC | 3.96e-04 | 7.29e-02 | 0.1278 |
| 9513 | FXR2 | P20T-E | Human | Esophagus | ESCC | 8.88e-06 | 3.89e-02 | 0.1124 |
| 9513 | FXR2 | P21T-E | Human | Esophagus | ESCC | 1.76e-06 | 4.26e-02 | 0.1617 |
| 9513 | FXR2 | P23T-E | Human | Esophagus | ESCC | 2.77e-09 | 9.15e-02 | 0.108 |
| 9513 | FXR2 | P24T-E | Human | Esophagus | ESCC | 2.90e-11 | 1.10e-01 | 0.1287 |
| 9513 | FXR2 | P26T-E | Human | Esophagus | ESCC | 1.44e-05 | 1.45e-02 | 0.1276 |
| 9513 | FXR2 | P27T-E | Human | Esophagus | ESCC | 7.22e-12 | 8.05e-02 | 0.1055 |
| 9513 | FXR2 | P28T-E | Human | Esophagus | ESCC | 2.55e-06 | 9.64e-02 | 0.1149 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0008380111 | Esophagus | ESCC | RNA splicing | 336/8552 | 434/18723 | 1.74e-42 | 3.67e-39 | 336 |
| GO:0000375111 | Esophagus | ESCC | RNA splicing, via transesterification reactions | 248/8552 | 324/18723 | 3.05e-30 | 1.49e-27 | 248 |
| GO:0000377111 | Esophagus | ESCC | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 244/8552 | 320/18723 | 2.52e-29 | 1.07e-26 | 244 |
| GO:0000398111 | Esophagus | ESCC | mRNA splicing, via spliceosome | 244/8552 | 320/18723 | 2.52e-29 | 1.07e-26 | 244 |
| GO:1903311110 | Esophagus | ESCC | regulation of mRNA metabolic process | 210/8552 | 288/18723 | 3.25e-21 | 5.56e-19 | 210 |
| GO:0006401110 | Esophagus | ESCC | RNA catabolic process | 204/8552 | 278/18723 | 3.39e-21 | 5.66e-19 | 204 |
| GO:0034655110 | Esophagus | ESCC | nucleobase-containing compound catabolic process | 272/8552 | 407/18723 | 2.92e-18 | 2.90e-16 | 272 |
| GO:0006402110 | Esophagus | ESCC | mRNA catabolic process | 170/8552 | 232/18723 | 8.70e-18 | 8.00e-16 | 170 |
| GO:0006417111 | Esophagus | ESCC | regulation of translation | 304/8552 | 468/18723 | 1.53e-17 | 1.33e-15 | 304 |
| GO:0043484111 | Esophagus | ESCC | regulation of RNA splicing | 116/8552 | 148/18723 | 3.18e-16 | 2.38e-14 | 116 |
| GO:0050684110 | Esophagus | ESCC | regulation of mRNA processing | 109/8552 | 137/18723 | 3.51e-16 | 2.59e-14 | 109 |
| GO:004670018 | Esophagus | ESCC | heterocycle catabolic process | 286/8552 | 445/18723 | 1.12e-15 | 7.47e-14 | 286 |
| GO:0045727111 | Esophagus | ESCC | positive regulation of translation | 107/8552 | 136/18723 | 2.79e-15 | 1.68e-13 | 107 |
| GO:004427019 | Esophagus | ESCC | cellular nitrogen compound catabolic process | 288/8552 | 451/18723 | 3.03e-15 | 1.79e-13 | 288 |
| GO:0034250111 | Esophagus | ESCC | positive regulation of cellular amide metabolic process | 123/8552 | 162/18723 | 3.32e-15 | 1.93e-13 | 123 |
| GO:001943918 | Esophagus | ESCC | aromatic compound catabolic process | 295/8552 | 467/18723 | 1.09e-14 | 5.98e-13 | 295 |
| GO:190136118 | Esophagus | ESCC | organic cyclic compound catabolic process | 307/8552 | 495/18723 | 9.99e-14 | 4.80e-12 | 307 |
| GO:0048024111 | Esophagus | ESCC | regulation of mRNA splicing, via spliceosome | 78/8552 | 101/18723 | 8.72e-11 | 2.66e-09 | 78 |
| GO:006101319 | Esophagus | ESCC | regulation of mRNA catabolic process | 115/8552 | 166/18723 | 5.90e-10 | 1.49e-08 | 115 |
| GO:2001020110 | Esophagus | ESCC | regulation of response to DNA damage stimulus | 145/8552 | 219/18723 | 5.97e-10 | 1.50e-08 | 145 |
| Page: 1 2 3 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| FXR2 | SNV | Missense_Mutation | c.1099N>C | p.Tyr367His | p.Y367H | P51116 | protein_coding | tolerated(0.5) | benign(0.031) | TCGA-A8-A08R-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| FXR2 | SNV | Missense_Mutation | novel | c.787N>G | p.Ile263Val | p.I263V | P51116 | protein_coding | tolerated(0.08) | possibly_damaging(0.447) | TCGA-B6-A0I1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| FXR2 | SNV | Missense_Mutation | rs772910721 | c.238N>G | p.Arg80Gly | p.R80G | P51116 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-BH-A0C3-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | PD |
| FXR2 | SNV | Missense_Mutation | rs772910721 | c.238C>G | p.Arg80Gly | p.R80G | P51116 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-BH-A1FH-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
| FXR2 | SNV | Missense_Mutation | c.1751N>A | p.Arg584His | p.R584H | P51116 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.98) | TCGA-C8-A1HM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | CR | |
| FXR2 | SNV | Missense_Mutation | novel | c.1660N>A | p.Asp554Asn | p.D554N | P51116 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.984) | TCGA-GM-A3NW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | fluorouracil | SD |
| FXR2 | insertion | Frame_Shift_Ins | novel | c.1769_1770insTTTCATAAAA | p.Arg591PhefsTer6 | p.R591Ffs*6 | P51116 | protein_coding | TCGA-A7-A0CE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | ||
| FXR2 | insertion | Nonsense_Mutation | novel | c.1844_1845insGGGTAGTATGGTGAATGGGGTTTCATAAAACCTCCAACCTGCACC | p.Ile615delinsMetGlySerMetValAsnGlyValSerTerAsnLeuGlnProAlaPro | p.I615delinsMGSMVNGVS*NLQPAP | P51116 | protein_coding | TCGA-B6-A0I5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| FXR2 | deletion | Frame_Shift_Del | novel | c.1707delC | p.Asn570ThrfsTer2 | p.N570Tfs*2 | P51116 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
| FXR2 | deletion | Frame_Shift_Del | c.1619delN | p.Pro540GlnfsTer32 | p.P540Qfs*32 | P51116 | protein_coding | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 9513 | FXR2 | NA | methylphenidate | METHYLPHENIDATE | 29382897 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |